Statins Safe with Strong CYP3A4 or P-glycoprotein Inhibitors
When prescribing statins alongside strong CYP3A4 or P-glycoprotein inhibitors, use pravastatin, fluvastatin, rosuvastatin, or pitavastatin—these statins are NOT metabolized by CYP3A4 and have minimal interaction risk. 1
Avoid These Combinations
Never combine the following statins with strong CYP3A4/P-gp inhibitors:
- Simvastatin - contraindicated with cyclosporine, tacrolimus, everolimus, sirolimus 1
- Lovastatin - contraindicated with cyclosporine, tacrolimus, everolimus, sirolimus 1
- Pitavastatin - contraindicated with cyclosporine 1
These combinations cause 5- to 20-fold increases in statin exposure and have documented cases of rhabdomyolysis. 1
Safe Statin Choices with Strong Inhibitors
First-Line Options (No Dose Restriction Needed):
- Pravastatin - not metabolized by CYP3A4, though still shows 5- to 10-fold AUC increase with cyclosporine 1
- Fluvastatin - minimal CYP3A4 metabolism, 2- to 4-fold AUC increase with cyclosporine 1
- Rosuvastatin - not metabolized by CYP3A4, 7-fold AUC increase with cyclosporine 1
Dose Restrictions Required:
When using these safer statins with strong inhibitors (cyclosporine, tacrolimus, everolimus, sirolimus):
- Fluvastatin: Maximum 40 mg daily 1
- Pravastatin: Maximum 20 mg daily 1
- Rosuvastatin: Maximum 5 mg daily 1
Atorvastatin: Use with Extreme Caution
Atorvastatin may be considered with strong CYP3A4/P-gp inhibitors, but:
- Keep dose ≤10 mg daily 1
- Monitor creatinine kinase closely 1
- Watch for muscle-related symptoms 1
- Atorvastatin shows 6- to 15-fold AUC increases with cyclosporine and has documented rhabdomyolysis cases 1
Specific Inhibitor Guidance
With Amiodarone (CYP3A4 and P-gp inhibitor):
- Simvastatin: Maximum 20 mg daily (FDA-mandated after SEARCH trial showed 8.8-fold increased myopathy risk) 1
- Lovastatin: Limit dose, though specific maximum not established 1
- Pravastatin: No significant interaction, preferred choice 1
With Diltiazem or Verapamil (moderate CYP3A4 inhibitors):
- Simvastatin: Maximum 10 mg daily 1
- Lovastatin: Maximum 20 mg daily (verapamil label allows 40 mg) 1
- Preferred: Switch to pravastatin, rosuvastatin, or pitavastatin 1
With Conivaptan (potent CYP3A4 inhibitor):
- Causes 3-fold increase in simvastatin exposure 1
- Four case reports of muscle toxicity exist 1
- Use non-CYP3A4 statins
Clinical Pitfalls to Avoid
Don't assume all statins are interchangeable - The metabolic pathways differ dramatically. Simvastatin, lovastatin, and atorvastatin are CYP3A4 substrates; pravastatin, fluvastatin, rosuvastatin, and pitavastatin are not. 2
All statins are OATP1B1 substrates - Even "safe" statins show increased exposure with inhibitors like cyclosporine, just to a lesser degree than CYP3A4-metabolized statins. 1
P-glycoprotein matters too - Atorvastatin, lovastatin, pravastatin, and simvastatin are P-gp substrates, adding another layer of interaction risk beyond CYP3A4. 1
Real-world data shows frequent co-prescribing errors - Studies demonstrate 25-30% of patients on CYP3A4-metabolized statins receive concomitant CYP3A4 inhibitors, suggesting widespread lack of awareness. 3, 4
Monitoring Requirements
For any statin-inhibitor combination:
- Monitor creatinine kinase at baseline and with any muscle symptoms
- Educate patients about myopathy symptoms (muscle pain, weakness, dark urine)
- Consider dose reduction if creatinine kinase elevates >3-5x upper limit of normal without symptoms
- Stop statin immediately if rhabdomyolysis suspected (creatinine kinase >10x normal, renal dysfunction)
The safest approach: When a patient requires a strong CYP3A4 or P-gp inhibitor, proactively switch from simvastatin, lovastatin, or high-dose atorvastatin to pravastatin, fluvastatin, or rosuvastatin at appropriate doses. 1